Abstract
In February 2004, bevacizumab (Avastin; Genentech), an antibody against vascular endothelial growth factor, was approved by the US FDA for the first-line treatment of metastatic colorectal cancer, a leading cause of cancer deaths worldwide. As the first approved agent to target tumour angiogenesis, it now looks set to become a blockbuster, helped by anticipated approvals for other cancer types, including non-small-cell lung cancer and renal cell cancer.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Regulatory withdrawal of medicines marketed with uncertain benefits: the bevacizumab case study
Journal of Pharmaceutical Policy and Practice Open Access 19 October 2015
-
Early dissemination of bevacizumab for advanced colorectal cancer: a prospective cohort study
BMC Cancer Open Access 16 August 2011
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Ferrara, N. et al. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nature Rev. Drug Discov. 3, 391–400 (2004).
Folkman, J. Tumor angiogenesis: therapeutic implications. N. Engl. J. Med. 285, 1182–1186 (1971).
Kim, K. J. et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 362, 841–844 (1993).
Presta, L. G. et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res. 57, 4593–4599 (1997).
Parkin, D. M. et al. Cancer burden in the year 2000. The global picture. Eur. J. Cancer 37, S4–S66 (2001).
Hurwitz, H. et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 350, 2335–2342 (2004).
FDA labelling information [online], <http://www.fda.gov/cder/foi/label/2004/125085lbl.pdf> (2004).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Muhsin, M., Graham, J. & Kirkpatrick, P. Bevacizumab. Nat Rev Drug Discov 3, 995–996 (2004). https://doi.org/10.1038/nrd1601
Issue Date:
DOI: https://doi.org/10.1038/nrd1601
This article is cited by
-
Vascular stenosis in a child with visual pathway glioma treated with bevacizumab: a case report and review of literature
Child's Nervous System (2018)
-
Regulatory withdrawal of medicines marketed with uncertain benefits: the bevacizumab case study
Journal of Pharmaceutical Policy and Practice (2015)
-
Early dissemination of bevacizumab for advanced colorectal cancer: a prospective cohort study
BMC Cancer (2011)
-
Drugs, their targets and the nature and number of drug targets
Nature Reviews Drug Discovery (2006)